Restoring the Treg cell to Th17 cell ratio may alleviate HBV-related acute-on-chronic liver failure

Table 1 Clinical characteristics of subjects in hepatitis B virus-related acute-on-chronic liver failure, chronic hepatitis B, and normal control groups n (%)

	ACLF (n = 50)	CHB (n = 29)	NC (n = 20)
Male/female	42/8	24/5	16/4
Age (yr)	40.2 ± 12.0	34.4 ± 12.0	34.5 ± 9.2
ALT (IU/L)	176.6 ± 430.0	328.4 ± 386.8	22.3 ± 6.7
TBIL (μmol/L)	566.3 ± 133.5	68.8 ± 90.9	12.2 ± 2.3
INR	1.83 ± 0.44	1.09 ± 0.10	0.99 ± 0.03
HBeAg	17 (34)	18 (62.1)	NA
Anti-HBe	30 (60)	8 (27.6)	NA
HBVDNA (Log10 IU/mL)	5.25 ± 1.30	6.11 ± 1.28	NA
MELD score	22.5 ± 4.7	4.6 ± 6.5	-2.7 ± 1.9

This table shows the mean ± SD of age, alanine aminotransferase (ALT), total bilirubin (TBIL), international normalized ratio (INR), and hepatitis B virus (HBV) DNA of all patients. Model for End-stage Liver Disease (MELD) scores are shown for the HBV-related acute-on-chronic liver failure (ACLF) group, chronic hepatitis B (CHB) group, and normal control (NC) group. The proportion of patients positive for hepatitis B e antigen (HBeAg) or hepatitis B e antibody (anti-HBe) in the ACLF and CHB groups is also displayed. NA: Not available.